Screener
Krystal Biotech, Inc. KRYS Business Segments — Income Tax Expense (Benefit)
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 7:06 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001711279-26-000043
| (in thousands) | Three Months Ended / March 31, 2026 | March 31, 2025 |
|---|---|---|
| Total research and development | 15,331 | 14,256 |
| Selling, general and administrative | 41,014 | 32,647 |
| Income from operations | $53,689 | $36,252 |
| Other income | ||
| Interest and other income, net | 7,753 | 7,345 |
| Income before income taxes | $61,442 | $43,597 |
| Income tax expense | (5,510) | (7,864) |
| Net income | $55,932 | $35,733 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Krystal Biotech, Inc.'s business segments — income tax expense (benefit)?
- Krystal Biotech, Inc. (KRYS) reported business segments — income tax expense (benefit) of $5.51M in Q1 2026.
- How has Krystal Biotech, Inc.'s business segments — income tax expense (benefit) changed year-over-year?
- Krystal Biotech, Inc.'s business segments — income tax expense (benefit) decreased by 29.9% year-over-year, from $7.86M to $5.51M.
- What does business segments — income tax expense (benefit) mean?
- Income tax expense or benefit represents the amount of tax owed or the tax credit recognized by the segment based on its pre-tax income. This figure is influenced by statutory tax rates, deferred tax assets, and available tax credits.
Ask your AI about Krystal Biotech, Inc.'s business segments — income tax expense (benefit).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude